NCT06852365招募中2 期
Resistant Starch Usage in Polycystic Ovary Syndrome: Impact on Cardiometabolic Dysfunction and the Gut Microbiome (CORS-PCOS)
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Change in Bifidobacteria abundance measured by quantitative polymerase chain reaction (q-PCR)
研究概览
简要总结
This study will enroll women with PCOS to study the effects of first line therapy, oral contraceptive pills, and then either 12 weeks of resistant starch or 12 weeks of placebo to explore if resistant starch improves cardiometabolic parameters or impacts gut dysbiosis compared to placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Women between ages of 18-40 years with BMI greater than or equal to 25 kg/m² to less than or equal to 48 kg/m² diagnosed with PCOS defined by the Rotterdam criteria based on a history of chronic anovulation (8 or fewer periods), androgen excess [defined as total serum testosterone, free testosterone or a FAI greater than or equal to 90% of the upper limit of normal) or hirsutism (Ferriman-Gallwey score greater than 6 for Hispanics/ Black and greater than or equal to 2 for women of Asian descent)] and polycystic ovaries as defined by a pelvic ultrasound (20 or more follicles or ovarian vol greater than 10cm3) or elevated AMH.
- •For women with more regular bleeding patterns, but who are suspected to be experiencing periodic anovulatory bleeding, a midluteal progesterone (P4) level less than 3ng/dL will be evidence of ovulatory dysfunction and qualify as anovulation.
- •Women with only hyperandrogenic PCOS phenotype (hyperandrogenism + one more criteria) will be included to decrease the heterogeneity of the cohort and as metabolic risks are increased in these women compared to normo-androgenic women with PCOS.
- •Subjects should be willing to avoid pregnancy for the entire duration of the study.
排除标准
- •Subjects with other causes for irregular menses such as pregnancy, lactation, untreated hypothyroidism, untreated hyperprolactinemia and premature menopause.
- •Subjects with late onset adrenal hyperplasia
- •Subjects with history of bariatric surgery
- •Those who are unable to comply with the study procedures, for instance due to mental illness, substance abuse, or participation in other studies.
- •Subjects taking medications that affect weight or metabolic parameters (e.g. lipid lowering medications).
- •History of Crohn's disease and ulcerative colitis as well as current use of probiotics and laxatives are excluded.
- •Subjects could not have taken antibiotics for at least 3 months prior to randomization visit.
- •Subjects with greater than 20 g/day of dietary fiber intake based on pre-screening ASA-24 survey will be excluded.
- •Subjects with medical conditions that are contraindications to use of OCP and other medical conditions such as:
- •Type 1 or 2 diabetes
- •liver disease or dysfunctional liver (AST/ALT greater than 2x normal or a total bilirubin greater than 2.5 mg/dL)
- •renal disease (BUN greater than 30 mg/dL or serum creatinine greater than 1.4 mg/dL)
- •severe anemia (hemoglobin less than 10 mg/dL)
- •alcohol abuse
- •poorly controlled hypertension
- •TG greater than 250 mg/dl
- •chronic inflammatory conditions such as psoriasis
- •history of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident; known heart disease (New York Heart Association Class II or higher)
- •history of cervical carcinoma, endometrial carcinoma, or breast carcinoma, adrenal or ovarian tumor secreting androgens, and Cushing's syndrome -
研究组 & 干预措施
Placebo
Placebo Comparator
maltodextrin
干预措施: Maltodextrin (Dietary Supplement)
Resistant Starch
Active Comparator
wheat dextrin
干预措施: wheat dextrin (Dietary Supplement)
Resistant Starch
Active Comparator
wheat dextrin
干预措施: Oral Contraceptives, Low-Dose (Drug)
Placebo
Placebo Comparator
maltodextrin
干预措施: Oral Contraceptives, Low-Dose (Drug)
结局指标
主要结局
Change in Bifidobacteria abundance measured by quantitative polymerase chain reaction (q-PCR)
时间窗: Baseline and 12 weeks
Change in Single Chain Fatty Acids (SCFA)
时间窗: Baseline and 12 weeks
Change in LDL-C measure
时间窗: Baseline and 12 weeks
Change in fasting glucose measure
时间窗: Baseline and 12 weeks
Change in systolic blood pressure
时间窗: Baseline and 12 weeks
Change in diastolic blood pressure
时间窗: Baseline and 12 weeks
Change in BMI
时间窗: Baseline and 12 weeks
次要结局
未报告次要终点
研究者
Anuja Dokras
Founder's Professor in Women's Health
University of Pennsylvania
研究点 (1)
Loading locations...
相似试验
Unknown
4 期
Metformin in Step-down Regimen Versus Conventional Low Dose Step-up Protocol in Patients With PCOS Undergoing IVFPCOSInfertilityNCT01438190University of Modena and Reggio Emilia120
已完成
4 期
The Effects of OCP and Metformin on Clinical, Hormonal, Metabolic and Ultrasonographic Characteristics in PCOSPolycystic Ovary SyndromeNCT02866786S.C.B. Medical College and Hospital101
已完成
不适用
Potential Impact of Polycystic Ovarian Syndrome on Protein Modifications and AccumulationPolycystic Ovarian Syndrome (PCOS)OverweightObeseInsulin ResistanceNCT02105428Mayo Clinic44
已完成
不适用
The Female Health Dietary Intervention StudyPolycystic Ovary SyndromeMorbid ObesityNCT00779571The Hospital of Vestfold61
Unknown
不适用
The Effect of Polycystic Ovary Syndrome Treatment on MetabolomicsPolycystic Ovary SyndromeNCT04831151Inonu University42